BOULDER, Colo., Sept.
- European Commission approval applies to all 28 European Union member states, Liechtenstein, Iceland and Norway -
- BRAFTOVI + MEKTOVI demonstrated a median overall survival of 33.6 months in patients with advanced BRAF-mutant melanoma in Phase 3 COLUMBUS trial -
BOULDER, Colo., Aug.
-- FDA approved BRAFTOVI™ (encorafenib) in combination with MEKTOVI® (binimetinib) for advanced BRAF-mutant melanoma --
- Industry veteran brings strong commercial experience as Array commercializes BRAFTOVI™ + MEKTOVI® -
- Designation based on Phase 3 BEACON CRC safety lead-in data -
- Positive CHMP opinion is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival and over 30 months median overall survival -
Investors in Array BioPharma Inc. saw new options begin trading this week, for the March 2019 expiration.
BOULDER, Colo. , July 13, 2018 /PRNewswire/ -- Array BioPharma Inc.
- Approval based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival -
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
- Encore investor webcast presentation June 23, 2018 -
-- Combination of encorafenib and binimetinib achieved 33.6 month median overall survival --
Investors in Array BioPharma Inc. saw new options begin trading this week, for the December 21st expiration.
A fresh look at all 17 ideas: the winners, the losers and the still to be determined.
Despite biotech losing a bit of its former headline grabbing attention, there are still plenty of great setups to be found.
Pomerantz LLP announces that a class action lawsuit has been filed against Array Biopharma Inc.
The most recent short interest data has been released for the 12/15/2017 settlement date, which shows a 4,831,803 share decrease in total short interest for Array BioPharma Inc. , to 15,831,594, a decrease of 23.38% since 11/30/2017.
The Klein Law Firm notifies shareholders that a class action complaint has been filed on behalf of shareholders of Array Biopharma Inc.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Array Biopharma Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of...
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Array Biopharma Inc.
The Klein Law Firm notifies shareholders that a class action complaint has been filed on behalf of shareholders of Array Biopharma Inc.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Array Biopharma Inc.
Investors continued to rotate into domestic stocks seen benefiting from tax cuts, but without higher estimates, the gains could falter.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Array Biopharma Inc.
